Bedford Biotech

"Bedford Biotech" does not appear to be the formal name of a standalone company; in available biotech-context usage it most likely refers to Nanoscope Therapeutics, a Bedford, Texas-based ophthalmology biotechnology company. Nanoscope is developing ambient light-activated, disease-agnostic optogenetic gene therapies intended to restore vision in patients with retinal degenerative diseases. Its lead program, MCO-010, is being advanced for retinitis pigmentosa and Stargardt disease, with additional development interest in other inherited retinal dystrophies and dry age-related macular degeneration. As of early April 2026, the company describes MCO-010 under the brand name MOGENRY and says it is advancing a rolling Biologics License Application in the United States while building commercial-readiness and scaled manufacturing capabilities. The company positions its core differentiator as an intravitreal, mutation-agnostic therapy designed to work across multiple retinal degeneration subtypes.